ABSTRACT
Objective To study the anti-proliferation and apoptosis induction effect of cisplatin combined with Astragalus on human laryngeal cancer Hep-2 cells.Methods The proliferation inhibition of cisplatin and Astragalus alone or in combination on Laryngeal cancer Hep-2cells was measured by MTT assay.Effects of cisplatin and Astragalus alone or in combination on apoptosis of Hep-2 cells were detected by flow cytometry (FCM).Western blot was used to analyze the expressions of Bcl-2 and Bax proteins.Results The inhibition ratio of proliferation of Hep-2 cells was (53.83 ± 17.12) ％ in the astragalus group,(69.12 ± 27.12)％ in the cisplatin group,and (84.55 ± 27.84)％ in the cisplatin combined with Astragalus group,and was significantly greater than the control group (0％) (t =16.87,16.67,40.90,P ＜0.01),respectively.The apoptotic ratio of Hep-2 cells was (38.2 ± 13.6)％ in the astragalus group,(67.2 ± 17.8)％ in the cisplatin group,and (86.4 ± 25.1)％] in the cisplatin combined with Astragalus group,and was significantly greater than control group (17.1 ± 1.3) ％ (t =8.11,12.77,24.92,P ＜0.05),respectively.The effect in the combination group is better than the other group (t =11.33,9.37,P ＜ 0.01).The expressions of Bcl-2 and Bax proteins were changed.Conclusions The tumor-killing effect of cisplatin on laryngeal cancer Hep-2 cells could be enhanced significantly by the combination application of astragalus by the way of regulating the expression of Bcl-2/Bax.
ABSTRACT
INTRODUÇÃO: Quimiorradioterapia (QRT) concomitante adjuvante aumenta a sobrevida livre de doença (SLD) em pacientes portadores de carcinoma epidermóide de cabeça e pescoço (CECCP) de alto risco operados com intenção curativa, porém está associada a toxicidade não desprezível e seu impacto na sobrevida global (SG) é incerto. ERCC1 (Excision Repair Cross Complementing Group 1) é uma proteína com função crítica no reparo de DNA por excisão de nucleotídeos (NER) e está envolvido na resistência à quimio- e radioterapia. Neste trabalho tivemos como objetivos determinar a expressão da proteína ERCC1, a expressão do RNA mensageiro (mRNA) de ERCC1 e a ocorrência do polimorfismo de nucleotídeo único T19007C de ERCC1 em pacientes portadores de CECCP de alto risco, operados e tratados com QRT adjuvante, bem como o valor prognóstico destes marcadores. MÉTODOS: Trata-se de um estudo retrospectivo em pacientes portadores de CEC de cavidade oral, orofaringe, hipofaringe ou laringe, operados com intenção curativa e portadores de doença de risco alto ou intermediário. Pacientes elegíveis haviam sido tratados com QRT adjuvante: 60-70 Gy e cisplatina concomitante (100 mg/m2, dias 1, 22 e 43), não apresentavam metástases a distância e nem sinais de recidiva após cirurgia. A expressão da proteína ERCC1 foi avaliada por imunohistoquímica, através de um escore H semiquantitativo, obtido pelo produto da intensidade da coloração nuclear (0-3) pelo escore proporcional atribuído à porcentagem estimada de núcleos corados (0;0,1;0,5;1). O método da transcrição reversa e reação em cadeia da polimerase (PCR) em tempo real quantitativo foi utilizado para determinação da expressão do mRNA de ERCC1 em tecido de tumor primário, normalizada em relação à expressão da fração 18S do RNA ribossomal. Genotipagem de ERCC1 (códon 118) foi realizada por PCR - polimorfismo do tamanho do fragmento de restrição a partir de DNA genômico extraído de linfonodos normais destes pacientes, após digestão com...
BACKGROUND: Adjuvant concurrent chemoradiation (CRT) improves diseasefree survival (DFS) in patients diagnosed with head and neck squamous cell carcinoma (HNSCC) presenting with high-risk features treated with surgery with curative intent, but treatment-related toxicity is not negligible and its impact on overall survival (OS) is uncertain. ERCC1 (Excision Repair Cross Complementing Group 1) is a protein with a critical role in the nucleotide excision repair (NER) pathway, associated with resistance to chemo- and radiation therapy. We aimed here to study ERCC1 protein expression, ERCC1 messenger RNA (mRNA) expression and the single nucleotide polymorphism T19007C of ERCC1 as prognostic markers in HNSCC patients presenting with high-risk features treated with surgery and adjuvant CRT. METHODS: It is a retrospective study in patients with oral cavity, oropharynx, hypopharynx or larynx SCC submitted to radical surgery with curative intent and presenting with pathologic features of high- or intermediate-risk. Eligible patients were treated with adjuvant CRT: 60-70 Gy and concurrent cisplatin (100 mg/m2, days 1, 22 and 43), with no distant metastasis and no relapsed disease after surgery. ERCC1 protein expression was evaluated by immunohistochemistry, using a semi-quantitative H-score, calculated by multiplying the nuclear staining intensity (0-3) by the proportion score attributed to the percentage of positive tumor nuclei (0;0,1;0,5;1). Quantitative real-time reverse transcriptase polymerase chain reaction (PCR) assay was performed to determine ERCC1 mRNA expression in primary tumors tissue specimens. The ERCC1 mRNA expression was normalized using 18S fraction of ribosomal RNA expression as internal reference. ERCC1 (codon 118) genotypes were detected using PCR restriction fragment length polymorphism method carried out in genomic DNA extracted from normal lymph nodes. The PCR products were digested with BsrDI. RESULTS: 69 patients...
Subject(s)
Humans , Male , Female , Carcinoma, Squamous Cell/therapy , Cisplatin/pharmacology , Follow-Up Studies , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Prognosis , DNA Repair/geneticsABSTRACT
Objective To observe the effects of paclitaxel,mitomycin,5-FU and cisplatin on the proliferation of tongue carcinoma cells and to guide the reasonable using of chemotherapeutic drugs and avoids the side-effects.Methods The fresh tongue carcinoma tissues from surgery were collected and unicellular suspension were prepared.Then paclitaxel,mitomycin,5-FU and cisplatin were used to investigate the drug sensitivity on primary tongue carcinoma cells and a blank control group was set up.The inhibitory effects of chemotherapeutic drugs on the growth of tongue carcinoma cells and the cell cycle phases were observed by MTT colorimetry and flow cytometry.Results The inhibitory rates of paclitaxel,mitomycin and 5-FU on tongue carcinoma cell proliferation were 45.3%,37.3%,and 36.2%,respectively,and in control group it was 2.1%,the difference was significant(P